Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Objective To clarify the impact of digoxin on death and clinical outcomes across all
observational and randomised controlled trials, accounting for study designs and methods …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and
inhibit Na+/K+-ATPase. Members of this family have been in clinical use for many years for …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Background: Despite endorsement of digoxin in clinical practice guidelines, there exist
limited data on its safety in atrial fibrillation/flutter (AF). Objectives: The goal of this study was …

O objetivo desta Diretriz é servir de apoio e auxiliar os médicos nas decisões referentes aos
seus pacientes, elaborando orientações que podem ser úteis na prática médica. A adoção …

Cardiotonic steroids (CTS), long used to treat heart failure, are endogenously produced in
mammals. Among them are the hydrophilic cardenolide ouabain and the more hydrophobic …

The Na/K-ATPase (NKA), or Na pump, is a member of the P-type ATPase superfamily. In
addition to pumping ions across cell membrane, it is engaged in assembly of multiple …

Aims Digoxin is recommended for long-term rate control in paroxysmal, persistent, and
permanent atrial fibrillation (AF). While some analyses suggest an association of digoxin …